Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 1 of 2: GR values. - Dataset (ID:20364)

 Full screen view
Filter results: >>>>
Cell line Drug name Experimental replicate Timepoint Drug concentration Live cell count Average live cell count, DMSO control Average live cell count (time = 0) Log10(drug concentration) GR value Relative cell count (treatment versus DMSO) Cell doublings (DMSO control) Experiment name
HCC70 Pictilisib 1 72
3.2
 1105.0 3399.0 1279.8
0.505
 -0.099 0.325 1.409
HCC70 GDC0941 0 1 72
Hs 578T CAL-101 3 72
3.2
 3370.5 4189.5 571.3
0.505
 0.854 0.805 2.874
Hs578T CAL101 3
BT-549 Alpelisib 1 72
3.2
 4299.5 5499.0 1554.9
0.505
 0.747 0.782 1.822
BT549 BYL719 0 1 72
BT-549 MK2206 1 72
3.2
 6334.0 5457.0 1554.9
0.505
 1.170 1.160 1.811
BT549 MK2206 0 1 72
HCC70 Sirolimus 3 72
3.2
 2097.5 3026.3 517.3
0.505
 0.732 0.693 2.548
HCC70 Rapamycin 0 3 72
HCC1806 PI103 1 72
3.2
 9624.3 11113.3 1742.8
0.505
 0.895 0.866 2.673
HCC1806 PI103 0 1 72
HCC70 Pictilisib 3 72
3.2
 992.8 2827.0 517.3
0.505
 0.305 0.351 2.450
HCC70 GDC0941 0 3 72
BT-20 XL147 1 72
3.2
 5132.5 6311.0 1443.3
0.505
 0.815 0.813 2.128
BT20 XL147 0 1
Hs 578T Trametinib 1 72
3.2
 857.0 3601.0 873.1
0.505
 -0.009 0.238 2.044
Hs578T Trametinib 1
HCC70 Torin2 2 72
3.2
 187.8 2562.3 722.8
0.505
 -0.522 0.073 1.826
HCC70 Torin2 0 2 72
HCC38 PIK-93 2 72
3.2
 2011.0 2975.5 690.5
0.505
 0.661 0.676 2.107
HCC38 PIK93 0 2 72
HCC1806 MK2206 1 72
3.2
 8994.8 11692.5 1742.8
0.505
 0.818 0.769 2.746
HCC1806 MK2206 0 1 72
HCC38 Sirolimus 2 72
3.2
 1829.3 2971.8 690.5
0.505
 0.588 0.616 2.105
HCC38 Rapamycin 0 2 72
HCC1806 KIN001-244 1 72
3.2
 11439.0 11660.3 1742.8
0.505
 0.986 0.981 2.742
HCC1806 KIN001-244 0 1 72
HCC70 Buparlisib 3 72
3.2
 341.8 2804.3 517.3
0.505
 -0.156 0.122 2.439
HCC70 BKM120 0 3 72
BT-20 ZSTK474 1 72
3.2
 1504.8 5537.8 1443.3
0.505
 0.022 0.272 1.940
BT20 ZSTK474 0 1
HCC38 TGX221 2 72
3.2
 2709.3 2993.0 690.5
0.505
 0.908 0.905 2.116
HCC38 TGX221 0 2 72
BT-549 KIN001-244 1 72
3.2
 4812.3 5422.3 1554.9
0.505
 0.872 0.888 1.802
BT549 KIN001-244 0 1 72
HCC38 Trametinib 3 72
3.2
 1419.3 3307.5 1180.5
0.505
 0.132 0.429 1.486
HCC38 Trametinib 0 3 72
BT-549 AS605240 1 72
3.2
 4915.0 5429.5 1554.9
0.505
 0.893 0.905 1.804
BT549 AS605240 0 1 72
HCC38 MK2206 3 72
3.2
 2602.0 3214.0 1180.5
0.505
 0.728 0.810 1.445
HCC38 MK2206 0 3 72
HCC1806 Omipalisib 1 72
3.2
 569.3 11840.0 1742.8
0.505
 -0.333 0.048 2.764
HCC1806 GSK458 0 1 72
HCC70 Everolimus 1 72
3.2
 2369.0 3299.0 1279.8
0.505
 0.569 0.718 1.366
HCC70 Everolimus 0 1 72
BT-20 AS605240 2 72
3.2
 2797.5 3661.0 1018.6
0.505
 0.729 0.764 1.846
BT20 AS605240 0 2
BT-549 Omipalisib 1 72
3.2
 1043.3 5372.5 1554.9
0.505
 -0.200 0.194 1.789
BT549 GSK458 0 1 72